PARTNER 3: What you should know about low risk TAVR

Dr. Lars Svensson, Chairman of the Heart and Vascular Institute, and Dr. Samir Kapadia, Chairman of the Department of Cardiovascular Medicine, have been involved with PARTNER trials over many years. Together, they discuss the history of the PARTNER Transcatheter aortic valve replacement (TAVR) trials, the results of the low risk PARTNER 3 trial and what it means for patients with aortic stenosis, who should have TAVR and considerations for treatment of aortic stenosis in young patients. What should you know if you have aortic stenosis requiring treatment?